Approval · Notice of Compliance 5272 · 1995
MAXZIDE: Notice of Compliance 5272
Issued June 22, 1995
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 5272
- Date
- June 22, 1995
- Company
- Wyeth-Ayerst Canada Inc.St. Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Therapeutic class
- Diuretic, antihypertensive
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MAXZIDE | 02170639 | — |
| MAXZIDE | 02170647 | — |
Medicinal ingredients
- TRIAMTERENE 37.5 MG per TAB
- HYDROCHLOROTHIAZIDE 25 MG per TAB
- TRIAMTERENE 75 MG per TAB
- HYDROCHLOROTHIAZIDE 50 MG per TAB